logo-loader

Intellipharmaceutics International shares tumble 46% after FDA advisory committees decision

Last updated: 14:12 27 Jul 2017 EDT, First published: 09:12 27 Jul 2017 EDT

shutterstock_212432119
Intellipharmaceutics International shares took a hit today

Intellipharmaceutics International Inc (NASDAQ:IPCI) shares tumbled 46% on Nasdaq on disappointing FDA related news.

Two US FDA advisory committees voted 22 to 1 in finding that its New Drug Application (NDA) for Rexista abuse-deterrent oxycodone hydrochloride extended release tablets should not be approved at this time.

The candidate is aimed as an abuse and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for the relief of pain.

Chief executive of Intellipharmaceutics, Dr. Isa Odidi, said: "While we are disappointed with the Committees’ overall vote, we will endeavor to remedy the concerns raised by completing the necessary human abuse potential studies in relation to the intranasal and oral routes of abuse.

"We will continue to work with the FDA in progressing this file over the next few weeks as we approach the September 25, 2017 PDUFA date.”

Shares shed 46.39% to $1.34.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

57 minutes ago